Market Place
Sourcing Support
Zhejiang Tianyu Pharmaceutical Co. Limited on Health Canada Inspection List
07 Dec 2022 //
HEALTH CANADA
The FDA scolds Tianyu over repeat API production shortfalls
29 Sep 2022 //
FIERCEPHARMA
Zhejiang Tianyu Pharmaceutical Co., Ltd. Receives FDA Warning Letter
28 Sep 2022 //
FDA
Manufacturing sites in Germany & China hit with warning letters
27 Sep 2022 //
ENDPTS
EU, US Ban Manufacturer use of Valsartan From China’s Zhejiang Huahai
29 Sep 2018 //
RAPS
EMA review of impurities in sartan medicines
22 Sep 2018 //
PRESS RELEASE
EU Suspends Chinese Company From Manufacturing Valsartan Active Substances
20 Aug 2018 //
RAPS
Update on medicines containing valsartan from Zhejiang Tianyu
20 Aug 2018 //
EMA
Investigation of Valsartan products for evidence of API contamination
19 Aug 2018 //
SWISSMEDIC
Update on review of valsartan medicines due to detection of NDMA
10 Aug 2018 //
EMA
Tainted valsartan has been on the market for 4 years, FDA discovers
09 Aug 2018 //
FIERCE PHARMA
Two more Chinese pharma groups hit by drugs scandal
07 Aug 2018 //
ASIATIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.